New data from a post hoc subgroup analysis from the phase III TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- metastatic breast cancer.
Gilead Sciences, Inc. announced new data from a post hoc subgroup analysis from the Phase III TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) versus comparator chemotherapies (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies
The analysis examined progression-free survival (PFS) in the intention-to-treat population by HER2-immunohistochemistry (IHC) status, and the results demonstrated that Trodelvy improved median PFS vs. TPC in both HER2-low (IHC1+ and IHC2+/ISH-negative) and IHC0 groups.
HER 2 (low); Median PFS (months) Trodelvy arm (n = 149) 6.4.TPC arm ( n = 134) 4.2( Hazard ratio 95% confidence internal p-value 0.58 ( 0.42-0.79).IHC0 ; Trodelvy arm (n = 101) 5.0. TPC arm (n = 116) 3.4 ( Hazard ratio 95% confidence internal p-value 0.72 (0.51-1.00). ITT; Trodelvy arm (n =272) 5.5.TPC arm (n = 271) 4.0. Hazard ratio 95% confidence interval p-value 0.66 (0.53 – 0.83). p=0.0003.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.